YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
This study looks at new ways to decide when to start a second treatment for certain types of lymphoma, using a blood test. It aims to see if this approach is safe and effective in helping patients.
For: Diffuse large B-cell lymphomas (DLBCL · Diffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL · High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
This study looks at a new type of cell therapy, Yescarta, for people with certain types of slow-growing non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers are checking how well it works and if it's safe over many years.
For: Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin LymphomaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma
This study is looking at a special type of cell therapy, called CAR T-cell therapy (Yescarta), for people with a type of lymphoma called primary mediastinal B-cell lymphoma (PMBCL). It aims to see how well this treatment can get rid of the cancer after three months, especially if other treatments haven't worked.
For: Primary mediastinal large B-cell lymphoma (PMBCL)Germany